Relay Therapeutics Inc.
September 09, 2024 - by Joey Ramson
$RLAY stock gapped up this morning after interim data from an early-stage study of its combination drug of RLY-2608, with AstraZeneca’s Faslodex for breast cancer, showed it meaningfully extended the time patients lived without the disease worsening.
